Weitz & Luxenberg is accepting cases of patients with multiple sclerosis (MS) who suffered from an ischemic stroke, hemorrhagic stroke, head or neck (cervicocephalic) arterial dissection, or death due to these complications within three days of being administered Lemtrada (alemtuzumab).

In November 2018, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication warning of risk of strokes and tears in lining of arteries of the head and neck in MS patients who are administered Lemtrada, mandating labeling changes, including a boxed warning, the most serious type of label warning.

Lemtrada Stroke Symptoms in MS Patients

Lemtrada is approved for use by adults with relapsing types of MS, an autoimmune disease in which a person’s immune system attacks the myelin sheath (a protective cover) of nerves. Lemtrada is administered via infusion (drip) into a vein over four hours.

The FDA notes patients suffering from ischemic stroke, hemorrhagic stroke, or head or neck (cervicocephalic) arterial dissection as a result of Lemtrada may experience:

Sudden numbness or weakness in the face, legs, or arms, usually on one side of the body.

Sudden trouble with dizziness, walking, or loss of balance or coordination.

Sudden severe headache or neck pain.

The FDA also noted that in the reports that the FDA has received, these adverse events occurred within, at most, three days of administration of alemtuzumab.

W&L Can Help Patients Harmed by Lemtrada

Attorneys in Weitz & Luxenberg’s Drugs & Medical Device unit are interested in hearing from patients with MS who have experienced an ischemic stroke, hemorrhagic stroke, head or neck (cervicocephalic) arterial dissection, or death due to these complications within three days of being administered Lemtrada (alemtuzumab).

An experienced Weitz & Luxenberg attorney can help you and your family explore your legal options, including if you may be entitled to financial compensation for medical expenses, pain and suffering, and lost wages.